Developer docs
API playgroundTry for free, no card

Search company profiles

Tiny Cargo

Full company profile

uuid0004j2i

Namestring
Tiny Cargo
Legal namestring
The Tiny Cargo Company, Inc.
Websiteurl
tinycargo.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

The Tiny Cargo Company, Inc. is a privately held biotechnology company founded in 2018 as a spinout from Virginia Tech's Fralin Biomedical Research Institute, headquartered in Roanoke, Virginia. The company has developed a proprietary platform for isolating exosomes from bovine milk at industrial scale — concentrations reported as 10,000 to 100,000 times greater than cell-culture supernatant yields — and a precision drug loading technology that achieves over 90% encapsulation efficiency across drug classes including peptides, monoclonal antibodies (up to 200 kDa), antisense oligonucleotides, mRNA, miRNA and small molecules. The platform enables oral bioavailability of biologics that historically required injection, demonstrates natural tissue homing to injured and inflamed sites, reduces first-pass liver filtration from over 90% to approximately 10%, and crosses the blood-brain barrier.

The company operates a B2B platform-licensing and partnership model targeting pharmaceutical and cosmeceutical companies, complemented by raw material sales of pharmaceutical-grade milk exosomes and internal development of a proprietary drug candidate, XOlacta, which uses milk exosomes to deliver the alphaCT11 peptide as an oral cardioprotectant and radioprotectant. Its go-to-market relies on direct enterprise engagement, scientific publications, white papers, and inquiry-based pricing for samples and licensing. In February 2026 the company opened a $1.5 million, 2,000+ square foot purpose-built cGMP-aligned cleanroom manufacturing facility in Roanoke — among the first dedicated exosome advanced manufacturing sites globally — and added six new R&D, manufacturing and regulatory roles. Customers to date are undisclosed; GRAS status from the FDA covers cosmetic and food applications.

The company is led by Founder and President Professor Robert Gourdie (Heywood Fralin Endowed Professor at Virginia Tech), Chairman and CEO Alan Gourdie, CSO Spencer Marsh (originator of the milk exosome isolation process and lead PI on NSF/NIH/DoD-funded programs), and CFO Sherri Cook, with a board including Heywood Fralin, Richard Warburg and dairy bioprocessing advisor Professor Richard Archer. Total disclosed funding exceeds $5 million in non-dilutive federal grants (NSF, NIH, DoD), plus state-backed investment from Virginia Innovation Partnership Corporation's Virginia Venture Partners. March 2026 brought a strategic collaboration with Bio-Sourcing SA (Belgium) to co-develop orally administered monoclonal antibody therapies targeting adalimumab (Humira) and trastuzumab (Herceptin), with Clinical Trial Application submissions targeted for early 2027 and 2028.

Short descriptiontext

Tiny Cargo is a Roanoke, Virginia-based biotechnology firm that isolates milk-derived exosomes at industrial scale and licenses a precision drug loading platform to pharmaceutical partners for oral delivery of biologics including monoclonal antibodies, peptides, and RNA therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersRoanoke, United States
HQ citystring
Roanoke
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
milk exosome manufacturing, drug delivery platform, pharmaceutical exosomes, oral biologic delivery, exosome isolation services
Industry3 codes
PRIMARYAFAHAGAC
Whey Fractionation & Bioactive Ingredient Isolation (α-Lac, Lactoferrin, Immunoglobulins, GMP)
Agriculture & Food Production/Dairy Processing/Whey Processing & Whey Ingredients (WPC/WPI, Lactose, Permeate)
SECONDARYAFAKAKAF
Whey, Casein & Milk Protein Ingredient Manufacturing
SECONDARYAFAHAHAI
Human Milk Fortifier (HMF) Manufacturing (Bovine-Derived)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Dry, Condensed, and Evaporated Dairy Product Manufacturing311514
  • Dairy Product Manufacturing3115
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Dairy Products2020
Product category
Drug Delivery Technology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Platform Licensing to Pharmaceutical Partners
TypeLicensing Royalties
Description

Licensing access to high-efficiency, functionality-preserving loading technology for pharmaceutical companies seeking to enhance delivery of their own therapeutic candidates. Expert team collaborates with partners to optimize exosome loading and accelerate drug development pipelines.

tinycargo.com
2Milk Exosome Product Sales
TypeOne Time License
Description

Sale of pharmaceutical-grade milk exosomes for use in drug formulations. Products available at grades suitable for pharmaceutical applications. cGMP-aligned commercial specification achieved.

tinycargo.com
3Proprietary Drug Development (XOlacta)
TypeSubscription Recurring
Description

Development and potential commercialization of proprietary drug candidate XOlacta, an orally-administered cardioprotectant and radioprotectant using alphaCT11 peptide loaded into milk exosomes.

tinycargo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain
Pricing details1 tier
1Pharmaceutical Grade Milk Exosomes
ModelOtherBilling cadencePay-as-you-go
Notes

Quote-based pricing for pharmaceutical-grade milk exosome products. Sample requests available through contact form on website.

tinycargo.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1XOlacta
Description

Proprietary drug product containing alphaCT11 peptide loaded into milk exosomes, being developed as an orally-administered cardioprotectant and radioprotectant.

tinycargo.com
Core offering1 text field

Tiny Cargo develops and manufactures an industrial-scale drug delivery system based on bovine milk-derived exosomes. It isolates pure, stable exosome concentrate from cow's milk at kilogram scale, then precision-loads therapeutic cargoes (peptides, monoclonal antibodies, RNA therapeutics, ASOs, mRNA, small molecules) into the exosomes at greater than 90% efficiency. Offerings include the pharmaceutical drug loading platform licensed to partners, pharmaceutical-grade milk exosomes sold as a raw input, cosmeceutical-grade exosomes, and the proprietary oral drug candidate XOlacta (alphaCT11 peptide loaded into milk exosomes for cardioprotection and radioprotection).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 40-70% increase in survival rates from single dose of XOlacta when given before or up to 24 hours following radiation exposure
+5 more records
Product overview1 text field

The Tiny Cargo Company offers a portfolio of products centered on its proprietary milk exosome technology. The core offering is the Pharmaceutical Drug Loading Platform, which enables precise encapsulation of therapeutic cargoes (peptides, RNAs, biologics, monoclonal antibodies, small molecules) within industrially-scaled milk-derived exosomes at over 90% efficiency. The lead proprietary drug candidate is XOlacta, which combines these milk exosomes with the αCT11 peptide for cardioprotective and radioprotective applications. The company also supplies Pharmaceutical Grade Milk Exosomes as a raw material for pharmaceutical partners, and Cosmeceutical Milk Exosomes for skincare formulations. The platform leverages milk exosomes' natural ability to survive gastric degradation, cross the gut lining, and home to injured tissue.

Product and service4 records
1XOlacta
CategoryProprietary drug candidate
Description

XOlacta is Tiny Cargo's first-in-class proprietary drug candidate, combining milk-derived exosomes loaded with the alphaCT11 peptide. It is being advanced as an orally administered cardioprotectant and systemically-effective radioprotectant designed to reduce cardiac injury following myocardial infarction and to protect healthy cells during radiation therapy. The alphaCT11 peptides are delivered directly to cells via milk exosomes, arresting the bystander effect to prevent the cascade of cell death and fibrosis. XOlacta is being developed for healthcare providers and patients requiring cardioprotection post myocardial infarction, radioprotection during cancer treatment, and medical countermeasures for radiation exposure.

2Pharmaceutical Drug Loading Platform
CategoryLicensed drug delivery technology platform
Description

Licensed platform enabling precise encapsulation of peptides, RNAs, biologics, and small molecules within milk exosomes, purpose-designed for pharmaceutical partners developing next-generation therapeutics. The platform achieves greater than 90% loading efficiency across drug classes including peptide therapeutics, monoclonal antibodies up to 150 kDa, antisense oligonucleotides, mRNA, miRNA, and small molecules, and combines natural biocompatibility with targeted delivery via oral administration. Tiny Cargo's expert team collaborates with partners to optimize exosome loading and accelerate drug development pipelines.

3Pharmaceutical-Grade Milk Exosomes
CategoryPharmaceutical raw material / exosome product
Description

Industrially-scaled milk-derived exosomes isolated from bovine milk using Tiny Cargo's proprietary process, available at grades suitable for pharmaceutical applications and serving as the foundational delivery vehicle for the company's therapeutic platform. The product achieves cGMP-aligned commercial specification, is offered at quote-based pricing, and is supplied to pharmaceutical partners through inquiry-based sales.

4Cosmeceutical Milk Exosomes
CategoryCosmeceutical exosome product
Description

Milk-derived exosomes for cosmetic formulations, marketed for enhancing skin health, regeneration, and delivery of active ingredients in skincare applications. Targeted at cosmeceutical companies seeking innovative bioactive ingredients for skin health, anti-aging, and wound healing products, with efficacy supported by published in vivo and in vitro data and GRAS status for milk exosomes under FDA regulations for cosmetic and food-related applications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-03-20
Description

Tiny Cargo was spun out from Virginia Tech's Fralin Biomedical Research Institute in 2018. Ongoing research collaborations and affiliation with the institute where founder Robert Gourdie serves as Heywood Fralin Endowed Professor.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

Strategic collaboration between Bio-Sourcing SA of Liège, Belgium and The Tiny Cargo Company to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes. Combines Bio-Sourcing's BioMilk transgenic goat milk production platform with Tiny Cargo's cGMP-ready industrial exosome extraction and loading technology. Initial programs target oral formulations of adalimumab (Humira) for Crohn's disease and trastuzumab (Herceptin) for HER2+ breast cancer, with Clinical Trial Application submissions targeted for early 2027 and 2028 respectively.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership to advance next-generation delivery of biologics, peptides and small molecules. Integrates Likarda's Core-Shell Spherification platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Spencer Marsh, CSO, has been a member of Johnson & Johnson's JLABS incubator program for life sciences startups.

5Blue Knight Incubator
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Spencer Marsh, CSO, has been a member of the Blue Knight Incubator for biotechnology startups.

rxglobal.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Oxford-based exosome therapeutics company developing engineered extracellular vesicles for drug delivery of nucleic acids, proteins, and small molecules. Most directly comparable to Tiny Cargo as a pure-play exosome drug delivery platform targeting similar pharmaceutical partner use cases.

TypeDirect peer
Description

Clinical-stage biotech developing cell-derived extracellular vesicle therapies (CAP-1002, CAP-2003) for cardiac and inflammatory indications. Comparable in extracellular vesicle approach and use of natural vesicles for therapeutic delivery, with more advanced clinical-stage assets.

3Aruna Bio
TypeDirect peer
Description

Developer of neural cell-derived exosomes (AB126) for neurological indications including stroke and ALS. Comparable as an exosome-based therapeutic platform targeting CNS delivery challenges, directly competing in the "natural vesicles for drug delivery" category.

TypeDirect peer
Description

Korean biotech developing engineered exosomes (EXO-LOAD platform) for intracellular protein therapeutic delivery. Directly comparable as a platform company that loads therapeutic cargoes into exosomes for pharmaceutical applications, similar to Tiny Cargo's drug loading platform.

TypeEmerging player
Description

Belgian biotech using transgenic goats to produce biotherapeutics in milk, including monoclonal antibodies. Direct strategic partner of Tiny Cargo and a partial competitor in the milk-derived therapeutic space — they use goat milk for biologics production while Tiny Cargo isolates exosomes from the same source.

TypeEmerging player
Description

Clinical-stage company developing purified exosome products (Purified Exosome Product, PEP) for wound healing, cardiac recovery, and aesthetic indications. Comparable in using exosomes as a therapeutic modality, with some cosmeceutical overlap with Tiny Cargo's cosmeceutical line.

TypeEmerging player
Description

Manufacturer of exosome-based products including cosmetic, regenerative, and research-grade exosome isolates from perinatal sources. Comparable to Tiny Cargo's cosmeceutical line and pharmaceutical-grade exosome product sales, with overlap in skin health and topical delivery applications.

TypeEmerging player
Description

South Korea-based exosome company commercializing exosome products for cosmetic and dermatological applications, including the EXOMAGE line. Most directly comparable in the cosmeceutical exosome segment where Tiny Cargo's Cosmeceutical Milk Exosomes compete.

TypeBroad incumbent
Description

Lipid nanoparticle (LNP) drug delivery platform serving pharmaceutical partners for nucleic acid and mRNA therapeutics, with significant overlap with Roivant/Roche-affiliated LNP technology. Comparable as a delivery technology platform enabling oral/systemic administration of fragile biologics, though using a different (non-exosome) delivery vehicle.

TypeEmerging player
Description

Clinical-stage regenerative medicine company developing extracellular vesicle products (ExoFlo) for inflammatory and immune-mediated conditions. Comparable in using extracellular vesicles as a therapeutic platform with broad anti-inflammatory applications, partially overlapping with Tiny Cargo's targeted homing and inflammation-based delivery claims.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tiny Cargo

Drug Delivery Technologytinycargo.com

Tiny Cargo is a Roanoke, Virginia-based biotechnology firm that isolates milk-derived exosomes at industrial scale and licenses a precision drug loading platform to pharmaceutical partners for oral delivery of biologics including monoclonal antibodies, peptides, and RNA therapeutics.

What Tiny Cargo does

The Tiny Cargo Company, Inc. is a privately held biotechnology company founded in 2018 as a spinout from Virginia Tech's Fralin Biomedical Research Institute, headquartered in Roanoke, Virginia. The company has developed a proprietary platform for isolating exosomes from bovine milk at industrial scale — concentrations reported as 10,000 to 100,000 times greater than cell-culture supernatant yields — and a precision drug loading technology that achieves over 90% encapsulation efficiency across drug classes including peptides, monoclonal antibodies (up to 200 kDa), antisense oligonucleotides, mRNA, miRNA and small molecules. The platform enables oral bioavailability of biologics that historically required injection, demonstrates natural tissue homing to injured and inflamed sites, reduces first-pass liver filtration from over 90% to approximately 10%, and crosses the blood-brain barrier.

The company operates a B2B platform-licensing and partnership model targeting pharmaceutical and cosmeceutical companies, complemented by raw material sales of pharmaceutical-grade milk exosomes and internal development of a proprietary drug candidate, XOlacta, which uses milk exosomes to deliver the alphaCT11 peptide as an oral cardioprotectant and radioprotectant. Its go-to-market relies on direct enterprise engagement, scientific publications, white papers, and inquiry-based pricing for samples and licensing. In February 2026 the company opened a $1.5 million, 2,000+ square foot purpose-built cGMP-aligned cleanroom manufacturing facility in Roanoke — among the first dedicated exosome advanced manufacturing sites globally — and added six new R&D, manufacturing and regulatory roles. Customers to date are undisclosed; GRAS status from the FDA covers cosmetic and food applications.

The company is led by Founder and President Professor Robert Gourdie (Heywood Fralin Endowed Professor at Virginia Tech), Chairman and CEO Alan Gourdie, CSO Spencer Marsh (originator of the milk exosome isolation process and lead PI on NSF/NIH/DoD-funded programs), and CFO Sherri Cook, with a board including Heywood Fralin, Richard Warburg and dairy bioprocessing advisor Professor Richard Archer. Total disclosed funding exceeds $5 million in non-dilutive federal grants (NSF, NIH, DoD), plus state-backed investment from Virginia Innovation Partnership Corporation's Virginia Venture Partners. March 2026 brought a strategic collaboration with Bio-Sourcing SA (Belgium) to co-develop orally administered monoclonal antibody therapies targeting adalimumab (Humira) and trastuzumab (Herceptin), with Clinical Trial Application submissions targeted for early 2027 and 2028.

Tiny Cargo firmographics

Firmographics
Name
Tiny Cargo
Legal name
The Tiny Cargo Company, Inc.
Website
https://tinycargo.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Tiny Cargo is a Roanoke, Virginia-based biotechnology firm that isolates milk-derived exosomes at industrial scale and licenses a precision drug loading platform to pharmaceutical partners for oral delivery of biologics including monoclonal antibodies, peptides, and RNA therapeutics.
Ownership category
akta.pro rank

Tiny Cargo industry classification

Industry
Product category
Drug Delivery Technology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Dry, Condensed, and Evaporated Dairy Product Manufacturing (311514), Dairy Product Manufacturing (3115)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Dairy Products (2020)
akta.pro industry
PRIMARYAFAHAGAC
Whey Fractionation & Bioactive Ingredient Isolation (α-Lac, Lactoferrin, Immunoglobulins, GMP)
Agriculture & Food Production/Dairy Processing/Whey Processing & Whey Ingredients (WPC/WPI, Lactose, Permeate)
SECONDARYAFAKAKAF
Whey, Casein & Milk Protein Ingredient Manufacturing
SECONDARYAFAHAHAI
Human Milk Fortifier (HMF) Manufacturing (Bovine-Derived)
Agriculture & Food Production/Dairy Processing/Infant Formula & Specialized Dairy Nutrition Manufacturing

Keywords

  • Milk exosome manufacturing
  • Drug delivery platform
  • Pharmaceutical exosomes
  • Oral biologic delivery
  • Exosome isolation services

Where Tiny Cargo is headquartered

Location

Headquarters

HQ city
Roanoke
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Tiny Cargo business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain

Revenue model

  1. Platform Licensing to Pharmaceutical Partners: Licensing access to high-efficiency, functionality-preserving loading technology for pharmaceutical companies seeking to enhance delivery of their own therapeutic candidates. Expert team collaborates with partners to optimize exosome loading and accelerate drug development pipelines.
  2. Milk Exosome Product Sales: Sale of pharmaceutical-grade milk exosomes for use in drug formulations. Products available at grades suitable for pharmaceutical applications. cGMP-aligned commercial specification achieved.
  3. Proprietary Drug Development (XOlacta): Development and potential commercialization of proprietary drug candidate XOlacta, an orally-administered cardioprotectant and radioprotectant using alphaCT11 peptide loaded into milk exosomes.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPharmaceutical Grade Milk Exosomes

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Tiny Cargo product offering

Product offering

Core offering

Tiny Cargo develops and manufactures an industrial-scale drug delivery system based on bovine milk-derived exosomes. It isolates pure, stable exosome concentrate from cow's milk at kilogram scale, then precision-loads therapeutic cargoes (peptides, monoclonal antibodies, RNA therapeutics, ASOs, mRNA, small molecules) into the exosomes at greater than 90% efficiency. Offerings include the pharmaceutical drug loading platform licensed to partners, pharmaceutical-grade milk exosomes sold as a raw input, cosmeceutical-grade exosomes, and the proprietary oral drug candidate XOlacta (alphaCT11 peptide loaded into milk exosomes for cardioprotection and radioprotection).

Product overview

The Tiny Cargo Company offers a portfolio of products centered on its proprietary milk exosome technology. The core offering is the Pharmaceutical Drug Loading Platform, which enables precise encapsulation of therapeutic cargoes (peptides, RNAs, biologics, monoclonal antibodies, small molecules) within industrially-scaled milk-derived exosomes at over 90% efficiency. The lead proprietary drug candidate is XOlacta, which combines these milk exosomes with the αCT11 peptide for cardioprotective and radioprotective applications. The company also supplies Pharmaceutical Grade Milk Exosomes as a raw material for pharmaceutical partners, and Cosmeceutical Milk Exosomes for skincare formulations. The platform leverages milk exosomes' natural ability to survive gastric degradation, cross the gut lining, and home to injured tissue.

Differentiator

Problem solved

Functional benefit

Brands

  • XOlacta: Proprietary drug product containing alphaCT11 peptide loaded into milk exosomes, being developed as an orally-administered cardioprotectant and radioprotectant.

Products and services

  • XOlacta XOlacta is Tiny Cargo's first-in-class proprietary drug candidate, combining milk-derived exosomes loaded with the alphaCT11 peptide. It is being advanced as an orally administered cardioprotectant and systemically-effective radioprotectant designed to reduce cardiac injury following myocardial infarction and to protect healthy cells during radiation therapy. The alphaCT11 peptides are delivered directly to cells via milk exosomes, arresting the bystander effect to prevent the cascade of cell death and fibrosis. XOlacta is being developed for healthcare providers and patients requiring cardioprotection post myocardial infarction, radioprotection during cancer treatment, and medical countermeasures for radiation exposure.
  • Pharmaceutical Drug Loading Platform Licensed platform enabling precise encapsulation of peptides, RNAs, biologics, and small molecules within milk exosomes, purpose-designed for pharmaceutical partners developing next-generation therapeutics. The platform achieves greater than 90% loading efficiency across drug classes including peptide therapeutics, monoclonal antibodies up to 150 kDa, antisense oligonucleotides, mRNA, miRNA, and small molecules, and combines natural biocompatibility with targeted delivery via oral administration. Tiny Cargo's expert team collaborates with partners to optimize exosome loading and accelerate drug development pipelines.
  • Pharmaceutical-Grade Milk Exosomes Industrially-scaled milk-derived exosomes isolated from bovine milk using Tiny Cargo's proprietary process, available at grades suitable for pharmaceutical applications and serving as the foundational delivery vehicle for the company's therapeutic platform. The product achieves cGMP-aligned commercial specification, is offered at quote-based pricing, and is supplied to pharmaceutical partners through inquiry-based sales.
  • Cosmeceutical Milk Exosomes Milk-derived exosomes for cosmetic formulations, marketed for enhancing skin health, regeneration, and delivery of active ingredients in skincare applications. Targeted at cosmeceutical companies seeking innovative bioactive ingredients for skin health, anti-aging, and wound healing products, with efficacy supported by published in vivo and in vitro data and GRAS status for milk exosomes under FDA regulations for cosmetic and food-related applications.

Quantifiable outcome

  • 40-70% increase in survival rates from single dose of XOlacta when given before or up to 24 hours following radiation exposure
  • +5 more outcomes

Companies that use Tiny Cargo

Customer profile

Segments4 records

Ideal customer profiles3 records

Tiny Cargo technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Tiny Cargo partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Fralin Biomedical Research Institute at Virginia TechcoreTechnology or Integration · 20 March 2026Tiny Cargo was spun out from Virginia Tech's Fralin Biomedical Research Institute in 2018. Ongoing research collaborations and affiliation with the institute where founder Robert Gourdie serves as Heywood Fralin Endowed Professor.
  • Bio-Sourcing SAcoreStrategic or Co-development Partner · 18 March 2026Strategic collaboration between Bio-Sourcing SA of Liège, Belgium and The Tiny Cargo Company to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes. Combines Bio-Sourcing's BioMilk transgenic goat milk production platform with Tiny Cargo's cGMP-ready industrial exosome extraction and loading technology. Initial programs target oral formulations of adalimumab (Humira) for Crohn's disease and trastuzumab (Herceptin) for HER2+ breast cancer, with Clinical Trial Application submissions targeted for early 2027 and 2028 respectively.
  • Likarda, Inc.coreStrategic or Co-development PartnerStrategic partnership to advance next-generation delivery of biologics, peptides and small molecules. Integrates Likarda's Core-Shell Spherification platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization.
  • JLABSminorStrategic or Co-development PartnerSpencer Marsh, CSO, has been a member of Johnson & Johnson's JLABS incubator program for life sciences startups.
  • Blue Knight IncubatorminorStrategic or Co-development PartnerSpencer Marsh, CSO, has been a member of the Blue Knight Incubator for biotechnology startups.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Tiny Cargo competitors and assessment

Company assessment

Direct peers

  • Evox Therapeutics: Oxford-based exosome therapeutics company developing engineered extracellular vesicles for drug delivery of nucleic acids, proteins, and small molecules. Most directly comparable to Tiny Cargo as a pure-play exosome drug delivery platform targeting similar pharmaceutical partner use cases.
  • Capricor Therapeutics: Clinical-stage biotech developing cell-derived extracellular vesicle therapies (CAP-1002, CAP-2003) for cardiac and inflammatory indications. Comparable in extracellular vesicle approach and use of natural vesicles for therapeutic delivery, with more advanced clinical-stage assets.
  • Aruna Bio: Developer of neural cell-derived exosomes (AB126) for neurological indications including stroke and ALS. Comparable as an exosome-based therapeutic platform targeting CNS delivery challenges, directly competing in the "natural vesicles for drug delivery" category.
  • ILIAS Biologics: Korean biotech developing engineered exosomes (EXO-LOAD platform) for intracellular protein therapeutic delivery. Directly comparable as a platform company that loads therapeutic cargoes into exosomes for pharmaceutical applications, similar to Tiny Cargo's drug loading platform.

Emerging players

  • Bio-Sourcing SA: Belgian biotech using transgenic goats to produce biotherapeutics in milk, including monoclonal antibodies. Direct strategic partner of Tiny Cargo and a partial competitor in the milk-derived therapeutic space — they use goat milk for biologics production while Tiny Cargo isolates exosomes from the same source.
  • Rion (previously known as Rion LLC): Clinical-stage company developing purified exosome products (Purified Exosome Product, PEP) for wound healing, cardiac recovery, and aesthetic indications. Comparable in using exosomes as a therapeutic modality, with some cosmeceutical overlap with Tiny Cargo's cosmeceutical line.
  • Kimera Labs: Manufacturer of exosome-based products including cosmetic, regenerative, and research-grade exosome isolates from perinatal sources. Comparable to Tiny Cargo's cosmeceutical line and pharmaceutical-grade exosome product sales, with overlap in skin health and topical delivery applications.
  • ExoCoBio: South Korea-based exosome company commercializing exosome products for cosmetic and dermatological applications, including the EXOMAGE line. Most directly comparable in the cosmeceutical exosome segment where Tiny Cargo's Cosmeceutical Milk Exosomes compete.
  • Direct Biologics: Clinical-stage regenerative medicine company developing extracellular vesicle products (ExoFlo) for inflammatory and immune-mediated conditions. Comparable in using extracellular vesicles as a therapeutic platform with broad anti-inflammatory applications, partially overlapping with Tiny Cargo's targeted homing and inflammation-based delivery claims.

Broad incumbents

  • Genevant Sciences: Lipid nanoparticle (LNP) drug delivery platform serving pharmaceutical partners for nucleic acid and mRNA therapeutics, with significant overlap with Roivant/Roche-affiliated LNP technology. Comparable as a delivery technology platform enabling oral/systemic administration of fragile biologics, though using a different (non-exosome) delivery vehicle.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Tiny Cargo social profiles

Digital presence

Tiny Cargo compliance and trust

Trust signal

Compliance1 record

Tiny Cargo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tiny Cargo leadership team

Management profile

Number of profiles

Profiles12 records

Tiny Cargo funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tiny Cargo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tiny Cargo

What does Tiny Cargo do?

Tiny Cargo develops and manufactures an industrial-scale drug delivery system based on bovine milk-derived exosomes. It isolates pure, stable exosome concentrate from cow's milk at kilogram scale, then precision-loads therapeutic cargoes (peptides, monoclonal antibodies, RNA therapeutics, ASOs, mRNA, small molecules) into the exosomes at greater than 90% efficiency. Offerings include the pharmaceutical drug loading platform licensed to partners, pharmaceutical-grade milk exosomes sold as a raw input, cosmeceutical-grade exosomes, and the proprietary oral drug candidate XOlacta (alphaCT11 peptide loaded into milk exosomes for cardioprotection and radioprotection).

Is Tiny Cargo a public or private company?

Tiny Cargo is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Tiny Cargo founded?

Tiny Cargo was founded in 2018. It employs 1 to 10 people.

Where is Tiny Cargo based?

Tiny Cargo is headquartered in Roanoke, United States, in the North America region.

How does Tiny Cargo make money?

Three revenue lines are on record. Platform Licensing to Pharmaceutical Partners are the primary driver. The others are milk Exosome Product Sales and proprietary Drug Development (XOlacta).

Who are Tiny Cargo's main competitors?

Direct peers on record are Evox Therapeutics, Capricor Therapeutics, Aruna Bio and ILIAS Biologics. Emerging players are Bio-Sourcing SA, Rion (previously known as Rion LLC), Kimera Labs, ExoCoBio and Direct Biologics. Genevant Sciences is listed as a broad incumbent.

Does Tiny Cargo have an API?

No public API is recorded for Tiny Cargo.

What industry is Tiny Cargo in?

Tiny Cargo's product category is Drug Delivery Technology. Its primary akta.pro industry code is AFAHAGAC, Whey Fractionation & Bioactive Ingredient Isolation (α-Lac, Lactoferrin, Immunoglobulins, GMP), with a secondary code of AFAKAKAF, Whey, Casein & Milk Protein Ingredient Manufacturing. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WVTFRoanoke leaders open biotech incubatorCity and state leaders in Virginia inaugurated RoVa Labs, a 40,000-square-foot biotech incubator located in the Roanoke Innovation Corridor. The facility was funded by a $15.7 million state grant and over $10 million in regional investment to support the commercialization of biomedical research. Tiny Cargo Company is the first tenant, utilizing the space for research and development alongside its manufacturing operations.PrwebLikarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small MoleculesLikarda, Inc., a hydrogel-based drug delivery technology company, announced a strategic partnership with Tiny Cargo, an extracellular vesicle delivery systems innovator, to advance the delivery of biologics, peptides, and small molecules. The collaboration will integrate Likarda's Core-Shell Spherification platform with Tiny Cargo's vesicle-based technologies to address key drug delivery challenges including poor stability, rapid clearance, and lack of localization.GenengnewsBio-Sourcing and Tiny Cargo Partner on Orally Delivered mAbs Using Goat Milk ExosomesLiège-based Bio-Sourcing and Roanoke-based The Tiny Cargo Company have entered a strategic collaboration to co-develop orally delivered monoclonal antibody therapies using goat milk-derived extracellular vesicles and exosomes, combining Bio-Sourcing's BioMilk® transgenic goat milk production platform with Tiny Cargo's cGMP-ready industrial exosome extraction and loading technology. The partnership aims to create patient-friendly oral biologics, with two initial programs targeting oral formulations of adalimumab (Humira) for Crohn's disease and trastuzumab (Herceptin) for HER2+ breast cancer, with Clinical Trial Application submissions targeted for early 2027 and 2028 respectively. The companies highlight that there are currently no approved oral mAbs, representing an innovative gap their alliance intends to address, with Tiny Cargo having opened a $1.5 million cGMP-ready manufacturing facility in Roanoke, VA in February 2026.PharmiWeb.comBio Sourcing and Tiny Cargo join forces to develop oral delivery therapies of monoclonal antibodies using goat milk exosomesBio-Sourcing SA of Liège, Belgium, and The Tiny Cargo Company of Roanoke, Virginia, USA, announced on March 18, 2026, a strategic collaboration to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes as delivery vehicles. The partnership combines Bio-Sourcing's platform for producing monoclonal antibodies in transgenic goat milk at industrial scale with Tiny Cargo's world-first cGMP-ready platform for purifying and loading milk-derived exosomes with therapeutic payloads. There are currently no approved oral mAbs on the market, making this alliance a bid to create a new class of patient-friendly, stable biologics that could eliminate needles and reduce hospital visits.PharmiWeb.comBio‑Sourcing and Tiny Cargo join forces to develop oral delivery therapies of monoclonal antibodies using goat‑milk exosomesBio-Sourcing SA of Belgium and The Tiny Cargo Company of Virginia, USA announced a strategic collaboration on March 18, 2026, to co-develop oral monoclonal antibody therapies using goat-milk extracellular vesicles and exosomes as delivery vehicles. The partnership combines Bio-Sourcing's scalable goat-milk production platform for mAbs and milk EVs with Tiny Cargo's cGMP-ready industrial exosome purification and loading technology. There are currently no approved oral mAbs on the market, making this alliance a bid to create a new class of patient-friendly, shelf-stable biologics that would eliminate the need for injections and reduce hospital visits.PharmiWeb.comTiny Cargo and Bio-Sourcing Partner to Develop First-of-Its-Kind Oral Monoclonal Antibody Platform Using Goat-Milk ExosomesThe Tiny Cargo Company and Bio-Sourcing SA announced a strategic partnership to develop an oral delivery platform for monoclonal antibodies using goat-milk-derived exosomes, combining Tiny Cargo's industrial-scale exosome isolation and loading capabilities with Bio-Sourcing's high-yield mAb production in goat milk. The collaboration aims to eliminate the need for injectable biologics by leveraging milk exosomes' natural ability to survive the gut environment and transport therapeutic molecules into the bloodstream. No FDA or EMA-approved oral mAbs currently exist, making this US-EU alliance a potential leader in addressing the 'needle barrier' that has historically limited biologics access.PR NewswireVIPC Empowers Life Science Startup Company, Tiny Cargo, in Opening New $1.5 Million Manufacturing Facility in RoanokeThe Virginia Innovation Partnership Corp. (VIPC) celebrated the grand opening of The Tiny Cargo Company's new $1.5 million manufacturing facility in Roanoke, Virginia, featuring over 2,000 square feet of specialized clean room space among the first dedicated exosome advanced manufacturing sites in the world. The facility will create six new high-paying jobs across research and development, cleanroom manufacturing, and regulatory operations. The company, founded by Dr. Robert Gourdie and spun out from Virginia Tech's Fralin Biomedical Research Institute in 2018, developed a patent-pending drug delivery platform using milk-derived exosomes for encapsulating therapeutics.MorningstarVIPC Empowers Life Science Startup Company, Tiny Cargo, in Opening New $1.5 Million Manufacturing Facility in RoanokeThe Virginia Innovation Partnership Corp. (VIPC) celebrated the grand opening of The Tiny Cargo Company's new $1.5 million manufacturing facility in Roanoke, Virginia, marking a milestone for the life science startup. The 2,000+ square foot clean room facility is among the first dedicated exosome advanced manufacturing sites globally and will create six high-paying jobs in research, manufacturing, and regulatory operations. The company, spun out from Virginia Tech's Fralin Biomedical Research Institute in 2018, is developing a drug delivery platform using milk-derived exosomes to encapsulate therapeutics for pharmaceutical and nutraceutical applications.The Roanoke Star NewsTechNite 2024 Celebrates The Elements of TechThe Roanoke-Blacksburg Technology Council held TechNite 2024 on May 8, honoring regional innovators with awards including the Hart of the Entrepreneur Impact Award to Tiny Cargo Co. and the Hall of Fame induction of Dr. Robert Sandel. Special guest Rishi Jaitly spoke on AI, and the event highlighted the region's technology ecosystem.NSFNSF Award SearchThe National Science Foundation awarded The Tiny Cargo Company a $216,000 grant for an STTR Phase I project to develop an oral drug delivery platform using milk exosomes to treat gastrointestinal radiation damage. The company successfully scaled its purification process from lab-scale to industrial levels and validated the efficacy of its therapeutic candidate, XoLacta, in treating radiation effects on cells.